Characterization of a single reporter-gene potency assay for T-cell-dependent bispecific molecules

Bispecific antibodies: a mechanistic review of the pipeline

(2019) Aran F. Labrijn et al.   NATURE REVIEWS DRUG DISCOVERY

Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapy

(2018) Charlotte de Wolf et al.   CYTOTHERAPY

Engineering therapeutic bispecific antibodies using CrossMab technology

(2018) Christian Klein et al.   METHODS

Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3

(2018) Dionysos Slaga et al.   Science Translational Medicine

“Two-in-One” approach for bioassay selection for dual specificity antibodies

(2017) Ho Young Lee et al.   JOURNAL OF IMMUNOLOGICAL METHODS

A high-performance, non-radioactive potency assay for measuring cytotoxicity: A full substitute of the chromium-release assay targeting the regulatory-compliance objective

(2017) Alexis Rossignol et al.   mAbs

The making of bispecific antibodies

(2017) Ulrich Brinkmann et al.   mAbs

Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies

(2017) Constantinos Petrovas et al.   Science Translational Medicine

ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy

(2017) Seandean Lykke Harwood et al.   OncoImmunology

T Cell Receptor-induced Nuclear Factor κB (NF-κB) Signaling and Transcriptional Activation Are Regulated by STIM1- and Orai1-mediated Calcium Entry

(2016) Xiaohong Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

(2015) C Krupka et al.   LEUKEMIA

Alternative molecular formats and therapeutic applications for bispecific antibodies

(2015) Christoph Spiess et al.   MOLECULAR IMMUNOLOGY

Ebola vaccine R&D: Filling the knowledge gaps

(2015) Donata Medaglini et al.   Science Translational Medicine

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

(2015) Weiqing Jing et al.   Journal for ImmunoTherapy of Cancer

Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies

(2014) Zhijie Jey Cheng et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay

(2012) Bhavin S. Parekh et al.   mAbs

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

(2012) C. F. McDonagh et al.   MOLECULAR CANCER THERAPEUTICS

Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains

(2011) Jürgen Schanzer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Akt Fine-tunes NF-κB-dependent Gene Expression during T Cell Activation

(2011) Jing Cheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

T Cell Activation

(2009) Jennifer E. Smith-Garvin et al.   Annual Review of Immunology

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

(2009) J. Bostrom et al.   SCIENCE

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE